Biotech startup developing dendritic cell-based therapies to control immunity for cancer treatment.
About
Guardian Bio is developing a dendritic cell-based platform for cancer therapy, focused on controlling immunity using next-generation cell therapies. Co-founded in 2022 by Ananya Zutshi (BSE Duke, MS/MBA Harvard, Blavatnik Fellow) and Ricky Barrett, the YC-backed company is pioneering novel approaches to immuno-oncology. Guardian Bio has raised $500K from investors including Creative Destruction Lab, Brazen Capital, and Fundament.
Tags
Total Employees
5
Current headcount
Performance
Company Timeline
No timeline data for this period
Score Breakdown
10Traction
36Team
0Visibility
15Profile
0Community
0Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Guardian Bio do?
Guardian Bio is developing a dendritic cell-based platform for cancer therapy, focused on controlling immunity using next-generation cell therapies. Co-founded in 2022 by Ananya Zutshi (BSE Duke, MS/MBA Harvard, Blavatnik Fellow) and Ricky Barrett, the YC-backed company is pioneering novel approaches to immuno-oncology. Guardian Bio has raised $500K from investors including Creative Destruction Lab, Brazen Capital, and Fundament.
How much funding has Guardian Bio raised?
Guardian Bio has raised a total of $500K in funding. The most recent round on record is Pre-Seed.
Where is Guardian Bio headquartered?
Guardian Bio is headquartered in United States.
When was Guardian Bio founded?
Guardian Bio was founded in 2022.
What industry does Guardian Bio operate in?
Guardian Bio operates in AI, Biotech, Immuno-Oncology, Cell Therapy.
How many employees does Guardian Bio have?
Guardian Bio has approximately 5 people on record.